Vaccitech

Vaccitech is a technology company.

Active

Updated: Mar 21, 2026 ·

About

Barinthus Biotherapeutics, formerly Vaccitech, is a clinical-stage biopharmaceutical company developing novel immunotherapies. It focuses on guiding T cells to address immunology and inflammatory conditions. Its technical approach utilizes antigen-specific immunotherapies, designed to combat chronic viral infections, autoimmune disorders, and cancers.

Vaccitech originated as an Oxford University spinout, founded by Professor Sarah Gilbert and Professor Adrian Hill. Their university research provided the key insight into leveraging T cells for therapeutic applications. In 2021, Vaccitech merged with Avidea Technologies, Inc. to form Barinthus Biotherapeutics, combining expertise and expanding development.

The company's efforts primarily benefit patients seeking advanced treatments for persistent diseases. Barinthus Biotherapeutics aims to advance the next generation of immunotherapies, enabling T cells to effectively manage and overcome various conditions. Its vision is to improve the lives of individuals grappling with chronic infectious diseases and autoimmune challenges.

Recent News & Mentions

Jan 1, 2021FundingVaccitech - Series B

Financial History

Vaccitech has raised $130.0M across 1 funding round. Most recently, it raised $130.0M Series B in January 2021.

Total Raised

$130.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Jan 1, 2021	$130.0M Series B		Future Planet Capital

Financial History

Vaccitech has raised $130.0M across 1 funding round.

Total Raised

$130.0M

Valuation

N/A

Deep Dive

Vaccitech is a clinical‑stage biopharmaceutical company that develops T‑cell‑focused vaccines and immunotherapies built on non‑replicating viral vector prime‑boost platforms (ChAdOx and MVA) and, more recently, complementary synthetic platforms acquired via Avidea/Barinthus technologies[4][1].[4][1]

High‑Level Overview

Vaccitech’s core activity: developing vaccines and T‑cell immunotherapies for infectious diseases, oncology and immune‑mediated conditions using a heterologous prime‑boost platform (chimpanzee adenoviral vectors ChAdOx1/ChAdOx2 as prime and Modified Vaccinia Ankara (MVA) as boost) and integrated technologies such as SNAPvax/SNAP‑based approaches added through acquisition[4][1].[4][1]- Who it serves: patients with infectious diseases (e.g., influenza, HBV, HPV), people at risk from viral infections and oncology patients where T‑cell responses against tumour antigens (e.g., MAGE‑A3, NY‑ESO‑1) are required; partners include academic institutes, CROs and larger pharma (AstraZeneca/Oxford relationship via the Oxford co‑invented COVID‑19 vaccine licensing history)[4][1].[4][1]- Problem solved: seeks to induce robust, durable CD8+ and CD4+ T‑cell responses that many traditional vaccine approaches do not, aiming to enable therapeutic vaccines for cancer and chronic infections as well as prophylactic vaccines where strong cellular immunity matters[4].[4]- Growth momentum: Vaccitech has advanced multiple clinical programs (Phase IIb influenza; programs for HBV, HPV, prostate cancer and cancer immunotherapies) and completed strategic deals and financings (institutional backers include GV/Sequoia China and a significant financing led by M&G), and expanded its platform via the Avidea acquisition to broaden pipeline and U.S. R&D presence[4][7][1].[4][7][1]

Origin Story

Founding and roots: Vaccitech traces to technology licensed from the Jenner Institute at the University of Oxford (the ChAdOx/MVA prime‑boost platform) and was spun out to commercialize non‑replicating viral vector T‑cell vaccines; it attracted venture and institutional investors including GV (Google Ventures), Sequoia China and Oxford Science Innovation early on[4][5].[4][5]- Key people / founders: the company grew from Oxford vaccine research (the Jenner Institute); executive leadership in recent press includes CEO Bill Enright and CSO Thomas Evans, with scientific lineage tied to Oxford and major vaccine research centers[1][4].[1][4]- How the idea emerged: the company commercialized academic prime‑boost viral vector work demonstrating strong CD8+ induction and portability into oncology and infectious disease programs; a pivotal real‑world validation was co‑inventing the Oxford‑based COVID‑19 vaccine technology that was licensed to AstraZeneca (Vaccitech is contractually entitled to milestone/royalty shares via Oxford University Innovation)[1].[1]- Early traction / pivotal moments: licensing of ChAdOx/MVA from Oxford, progression of multiple clinical programs into Phase II, significant institutional financings (including a $168M financing announced with M&G leadership) and the strategic acquisition of Avidea Technologies to add SNAPvax capabilities and U.S. R&D presence are key milestones[4][7][1].[4][7][1]

Core Differentiators

Platform potency: heterologous ChAdOx (chimp adenovirus) prime + MVA boost has been shown by Vaccitech to generate higher magnitudes of CD8+ T cells versus many competing approaches, making it attractive for T‑cell therapeutic vaccines[4].[4]- Multi‑platform strategy: addition of Avidea’s SNAPvax synthetic nanoparticle platform (SNAP) creates opportunities for prime‑boost mixing (ChAdOx + SNAPvax) to improve safety, manufacturability and antigen/payload flexibility across oncology, infectious disease and autoimmunity[1][2].[1][2]- Translational partnerships & academic pedigree: technology licensed from the Jenner Institute (Oxford) and collaborations with institutions such as Ludwig Cancer Research and Cancer Research UK provide access to validated tumor antigens, trial networks and translational expertise[4].[4]- Clinical pipeline breadth: simultaneous development across prophylactic vaccines (influenza, viral targets) and therapeutic oncology/infectious disease programs concentrates platform validation across indications[4][4].- Investor and capital backing: substantial institutional financing and notable investors (GV, Sequoia China, M&G, Oxford Science Innovation) support sustained R&D and clinical advancement[5][7].[5][7]

Role in the Broader Tech / Biotech Landscape

Trend alignment: Vaccitech rides the broader shift toward T‑cell‑centric immunotherapies and next‑generation vaccine platforms that prioritize cellular immunity, a trend amplified by the COVID‑19 experience and renewed interest in therapeutic vaccines for chronic infections and cancer[4][1].[4][1]- Timing advantages: advances in viral vector design, improved manufacturing processes, and regulatory familiarity with vector‑based vaccines (post‑COVID era) lower technical and commercial barriers for companies with proven platforms[1][4].[1][4]- Market forces in its favor: unmet need in therapeutic vaccines for HBV, HPV‑related disease, and many cancers, plus demand for versatile prime‑boost approaches that can be rapidly adapted to new antigens, create commercial opportunities for scalable platforms[4][1].[4][1]- Ecosystem influence: by commercializing Oxford‑derived vector platforms and partnering with leading research bodies, Vaccitech acts as a translational bridge—moving academic T‑cell vaccine science into clinical-stage programs and stimulating ecosystem activity around prime‑boost and synthetic nanoparticle immunotherapies[4][1].[4][1]

Quick Take & Future Outlook

Near term: expect Vaccitech to advance its clinical programs (ongoing Phase II/IIa trials in oncology and viral indications) and to integrate Avidea’s SNAPvax technology into new product candidates and prime‑boost regimens while expanding U.S. R&D operations[1][4].[1][4]- Key trends to watch: regulatory acceptance of vector‑based therapeutic vaccines post‑COVID, clinical readouts demonstrating durable T‑cell responses correlating with clinical benefit, and successful demonstration of mixed‑platform prime‑boost regimens (ChAdOx + SNAPvax) will materially affect valuation and strategic partnerships[1][4].[1][4]- Potential evolution of influence: if Vaccitech’s platforms show consistent clinical benefit in oncology or chronic infections, the company could become a platform licensor/partner for larger pharma and a leader in therapeutic vaccine commercialization; failure to translate T‑cell magnitude into clear clinical outcomes would temper that upside[4][1].[4][1]

Quick hook reconnected: Vaccitech sits at the intersection of proven academic vector science and emerging synthetic nanoparticle immunotherapies—if clinical results convert high magnitude T‑cell induction into durable patient benefit, Vaccitech’s platform and recent acquisitions position it to be a commercial leader in T‑cell vaccines and therapeutic immunotherapies[4][1].[4][1]

Notes: statements above are drawn from Vaccitech corporate and industry reporting on their ChAdOx/MVA platform, clinical programs and the Avidea acquisition[4][1][2][7].[4][1][2][7]

Sources

Frequently Asked Questions

How much funding has Vaccitech raised?

Vaccitech has raised $130.0M in total across 1 funding round.

Who are Vaccitech's investors?

Vaccitech's investors include Future Planet Capital.